Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genentech and Inotek Pharmaceuticals will jointly develop and commercialize inhibitors of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme involved in the repair of damaged DNA, for the treatment of cancer. Inotek will receive a $20 million up-front payment and could reap an additional $405 million in milestone payments. Genentech will pay Inotek royalties on its lead PARP inhibitor, INO-1001, currently in Phase Ib testing for skin cancer. As part of the deal, Genentech also has the option to develop Inotek's PARP inhibitors for cardiovascular indications. If exercised, the option could be worth another $200 million to Inotek.
This article has been sent to the following recipient: